Ocular surface strategies are a must for treating patients with glaucoma

Article

As a chronic disease, glaucoma requires long-term, lifetime treatment, often with multiple ophthalmic medications.

The prevalence of ocular surface disease (OSD) is high in glaucoma patients.1 A number of factors-including increased age and medications typically taken by seniors, such as antihypertensives, antidepressants, and antihistamines-can cause dry eye symptoms and OSD. Additionally, repeated exposure to certain preservatives used in glaucoma medications can exacerbate this condition.

In a study of 630 glaucoma or ocular hypertension patients on topical IOP-lowering medications, nearly half had OSD index scores reflecting at least mild OSD symptoms; more than a quarter were classified as having moderate or severe OSD.2

BAK toxicity

Although benzalkonium chloride (BAK) does a remarkable job of keeping multi-dose eye drops sterile, animal experiments and clinical studies have shown that BAK can have dose-dependent toxic effects, compromising tear film stability and causing irritation to the cornea and conjunctiva. These ocular side effects may cause symptoms such as stinging, burning, and dryness.1,4

Considerable evidence also shows that preservatives can compromise the integrity of the tear film through their detergent effect on the lipid layer. This reduces tear film stability, causing excessive evaporation and resulting in increased ocular dryness.5,6,7 An impaired tear film can predispose the eye to inflammation and conjunctival metaplasia.

In addition, preservatives can affect the goblet cells by reducing their number and production of the protective mucin layer.8 Other effects of excessive preservative use include conjunctival epithelium inflammation and subconjunctival fibrosis.1

The side effects associated with long-term use of preserved anti-glaucoma medications can also adversely impact patient compliance with therapy and the likelihood of successful treatment.9

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Paul Karpecki, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
© 2025 MJH Life Sciences

All rights reserved.